Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On July 19, 2022, Dr. Christos Kaskavelis submitted his resignation from the Board of Directors (the "Board") of Advent Technologies Holdings, Inc. (the "Company"). Dr. Kaskavelis was a Class III director with a term expiring at the Company's 2023 Annual Meeting of Stockholders. Dr. Kaskavelis will continue to serve as the Company's Chief Marketing Officer.

On July 20, 2022, the Board appointed Dr. Panoraia 'Nora' Gourdoupi as a director to fulfill the position vacated by Dr. Kaskavelis' resignation. She has been an employee of Advent since 2006 and is currently the Company's Senior Vice President of Corporate Business Developments. Dr. Gourdoupi will serve as a Class III director with a term expiring at the Company's 2023 Annual Meeting of Stockholders.

There are no arrangements or understandings between either Dr. Gourdoupi, on the one hand, and the Company or any other persons, on the other hand, pursuant to which Dr. Gourdoupi was selected as a director. Dr. Gourdoupi has no family relationships with any of the Company's directors or executive officers. Other than as described below, there are no related party transactions between the Company and Dr. Gourdoupi (or any of her respective immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. In connection with the Company's business combination, which closed on February 4, 2021, Dr. Gourdoupi was a party to a Voting Agreement, Lock-up Agreement, which expired in February 2022, and Non-Competition Agreement, all of which are described under "Certain Relationships and Related Transactions, and Director Independence" in Item 13 of Part IV of the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 31, 2022.

The Company will enter into its standard form of indemnification agreement with Dr. Gourdoupi. She will receive no compensation specific to her service as a director but will be compensated in accordance with her position as Senior Vice President of Corporate Business Developments.

Item 7.01 Regulation FD Disclosure.

On July 22, 2022, the Company issued a press release announcing the appointment of Dr. Gourdoupi as a director of the Company. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is not deemed to be "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall this item and Exhibit 99.1 be incorporated by reference into the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such future filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



  Exhibit No.   Description
    99.1        Press Release dated July 22, 2022.
  104           Cover Page Interactive Data File (embedded within the Inline XBRL
                document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses